Kevin Wilson Sells 1,912 Shares of BioSyent (CVE:RX) Stock

BioSyent Inc. (CVE:RX) insider Kevin Wilson sold 1,912 shares of the company’s stock in a transaction on Monday, March 30th. The shares were sold at an average price of C$11.15, for a total transaction of C$21,318.80. Following the completion of the sale, the insider directly owned 61,058 shares in the company, valued at approximately C$680,796.70. The trade was a 3.04% decrease in their ownership of the stock.

BioSyent Price Performance

Shares of RX opened at C$14.42 on Wednesday. The business’s 50-day moving average is C$14.60 and its two-hundred day moving average is C$12.77. The company has a market capitalization of C$165.79 million, a P/E ratio of 18.42 and a beta of 0.93. BioSyent Inc. has a fifty-two week low of C$9.20 and a fifty-two week high of C$15.80. The company has a debt-to-equity ratio of 2.03, a quick ratio of 6.91 and a current ratio of 5.51.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.